Leerink Partnrs Has Negative Outlook of TRVI FY2024 Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Equities researchers at Leerink Partnrs lowered their FY2024 earnings estimates for shares of Trevi Therapeutics in a report issued on Wednesday, November 6th. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earnings of ($0.49) per share for the year, down from their previous forecast of ($0.48). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.47) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics’ Q4 2024 earnings at ($0.13) EPS, FY2025 earnings at ($0.47) EPS and FY2026 earnings at ($0.45) EPS.

Other equities analysts also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Trevi Therapeutics in a research report on Tuesday, October 22nd. Leerink Partners assumed coverage on shares of Trevi Therapeutics in a report on Monday, September 9th. They issued an “outperform” rating and a $7.00 target price for the company. EF Hutton Acquisition Co. I upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, August 19th. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a research note on Friday. Finally, B. Riley reiterated a “buy” rating and issued a $6.00 price target on shares of Trevi Therapeutics in a report on Monday, October 7th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Trevi Therapeutics presently has an average rating of “Buy” and a consensus price target of $7.43.

Trevi Therapeutics Trading Up 0.3 %

Shares of NASDAQ TRVI opened at $2.91 on Monday. Trevi Therapeutics has a 12-month low of $0.97 and a 12-month high of $4.00. The firm’s 50-day moving average price is $3.15 and its 200-day moving average price is $2.91. The stock has a market capitalization of $223.68 million, a price-to-earnings ratio of -6.61 and a beta of 1.01.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter last year, the firm posted ($0.08) earnings per share.

Insider Activity

In other Trevi Therapeutics news, insider Thomas Sciascia sold 18,660 shares of the stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $2.76, for a total transaction of $51,501.60. Following the transaction, the insider now directly owns 220,315 shares in the company, valued at $608,069.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Jennifer L. Good sold 10,981 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total transaction of $33,162.62. Following the sale, the chief executive officer now owns 213,313 shares of the company’s stock, valued at $644,205.26. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Thomas Sciascia sold 18,660 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $2.76, for a total transaction of $51,501.60. Following the completion of the transaction, the insider now owns 220,315 shares of the company’s stock, valued at $608,069.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,355 shares of company stock worth $116,663. Company insiders own 24.37% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of TRVI. Logos Global Management LP grew its holdings in Trevi Therapeutics by 27.3% in the second quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock worth $8,344,000 after purchasing an additional 600,000 shares during the last quarter. Opaleye Management Inc. grew its stake in Trevi Therapeutics by 4.3% during the 1st quarter. Opaleye Management Inc. now owns 2,645,000 shares of the company’s stock worth $9,125,000 after buying an additional 110,000 shares during the last quarter. Vanguard Group Inc. increased its position in Trevi Therapeutics by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock valued at $7,948,000 after buying an additional 60,249 shares in the last quarter. Ally Bridge Group NY LLC purchased a new stake in Trevi Therapeutics in the second quarter valued at about $4,395,000. Finally, Rosalind Advisors Inc. boosted its holdings in Trevi Therapeutics by 50.3% in the second quarter. Rosalind Advisors Inc. now owns 1,391,577 shares of the company’s stock worth $4,147,000 after acquiring an additional 465,561 shares in the last quarter. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.